Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2003
10/09/2003WO2003082163A1 Adherent n,o-carboxymethylchitosan drug delivery devices for moist tissue and methods of their use
10/09/2003WO2003082139A1 Dispensing apparatus and cartridge
10/09/2003WO2003055445A3 Compositions and methods for enhancing corticosteriod delivery
10/09/2003WO2003049804A3 Treatment of genitourinary tract disorders
10/09/2003WO2003040686A3 Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
10/09/2003WO2003035032A3 New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
10/09/2003WO2003026621A3 Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product
10/09/2003WO2003026617A3 (ester)-lysolecithins in liposomes
10/09/2003WO2003005959A3 Amphiphilic star-like macromolecules for drug delivery
10/09/2003WO2002067846A8 A vaccine composition and method of using the same
10/09/2003US20030191540 Prosthetic foot with tunable performance
10/09/2003US20030191500 System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
10/09/2003US20030191446 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
10/09/2003US20030191431 External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
10/09/2003US20030191426 Device for enhanced delivery of biologically active substances and compounds in an organism
10/09/2003US20030191347 Venlafaxine base
10/09/2003US20030191300 Antisense modulation of bcl-x expression
10/09/2003US20030191286 Purification and characterization of soluble human HLA proteins
10/09/2003US20030191192 Aqueous suspension of drug; storage stability
10/09/2003US20030191187 Aqueous solution containing phosphate; adjustment pH
10/09/2003US20030191185 Hormone replacement therapy
10/09/2003US20030191183 Nasal administering; side effect reduction; bioavailability
10/09/2003US20030191180 Pharmaceutical compositions
10/09/2003US20030191179 Methods for administration of paclitaxel
10/09/2003US20030191178 Therapy for vision defects; hypotensive agents; respiratory system disorders
10/09/2003US20030191159 Antisecretory agents; antiulcer agents; adjust absorption
10/09/2003US20030191157 Injections
10/09/2003US20030191151 Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/09/2003US20030191147 Alcoholism, drug abuse, antidepressants
10/09/2003US20030191137 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
10/09/2003US20030191101 Sustained release; bioavailability; storage stability
10/09/2003US20030191093 Pharmaceutical compositions comprising active vitamin D compounds
10/09/2003US20030191090 Anemia therapy; hydrogenation dextrin; reacting with ferric salt; complexing
10/09/2003US20030191082 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
10/09/2003US20030191080 Cardiovascular disorders; hypotensive agents
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191070 Medical composition kit for treating lesioned abnormal tissue
10/09/2003US20030191057 Cardiovascular disorders; antiinflammatory agents
10/09/2003US20030191052 Infection therapy; binding of mannan lecithin to protein
10/09/2003US20030191043 Methods and formulations for enhancing the dissolution of a solid material in liquid
10/09/2003US20030190748 In the presence of fibroblast growth factor; allows stable prolifertion and differentiation while maintaining karyotype
10/09/2003US20030190387 Obtained by hydrolyzing pyrodextrin with amylase and debranching enzyme; (sugar-free) chewing gum
10/09/2003US20030190379 Dressing for treating burns
10/09/2003US20030190366 Particle formation
10/09/2003US20030190365 Mixing non-dihydrate azithromycin particles with granulating amount of granulating liquid and optionally excipients to form wet granules which comprise non-dihydrate azithromycin and the granulating liquid
10/09/2003US20030190364 Biological affinity based delivery systems
10/09/2003US20030190362 Pharmaceutically acceptable mixture of gelatin and hydrophobic polymer
10/09/2003US20030190361 Oxacarbazepine film-coated tablets
10/09/2003US20030190360 Chronotherapeutic pharmaceutical formulation comprising core containing active agent and delayed release compression coating comprising a natural or synthetic gum applied onto surface of core
10/09/2003US20030190359 Dosage forms for immediate release and stabilized compositions
10/09/2003US20030190358 Sustained release hydromorphone formulations exhibiting bimodal characteristics
10/09/2003US20030190357 Compositions for delivery of a cortisol antagonist
10/09/2003US20030190356 Process for preparing oral sustained-release formulation of felodipine
10/09/2003US20030190355 Modified release minerals
10/09/2003US20030190354 Venlafaxine hydrochloride in a matrix tablet dosage form, in which the the venlafaxine is mixed with a combination of hydrophillic and hydrophobic matrix forming components; antidepressant
10/09/2003US20030190353 Low water-soluble venlafaxine salts
10/09/2003US20030190352 Compositions of venlafaxine base
10/09/2003US20030190351 Venlafaxine hydrochloride and sodium carboxymethyl cellulose; antidepressant
10/09/2003US20030190350 Levothyroxine compositions having unique triiodothyronine Tmax properties
10/09/2003US20030190349 Methods of stabilizing pharmaceutical compositions
10/09/2003US20030190348 Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment
10/09/2003US20030190347 Use of nanodispersions in pharmaceutical end formulations
10/09/2003US20030190345 Plaster preparation
10/09/2003US20030190343 Palatable pharmaceutical compositions for companion animals
10/09/2003US20030190340 Gel formulations of 1-hydroxy-2(H)pyridone derivatives, which contain solvents and hydrophilic gel-forming agents
10/09/2003US20030190334 1S-(1 alpha ,3 alpha ,4 beta ))-2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl)-6H-puri n-6-one to treat hepatitis B virus infection
10/09/2003US20030190332 Engineered viral particle containing a group of co-expressed viral proteins or portions expressed in an edible plant material, adminstering such plant material containing viral vaccine to the gastrointenial mucosa of the patient
10/09/2003US20030190331 Vaccine composition and stabilisation method
10/09/2003US20030190323 Preparations and methods for the treatment of T cell mediated diseases
10/09/2003US20030190310 Primary package containing a low molecular weight peptide-based thrombin inhibitors sealed with a bromobutyl rubber stopper or plunger
10/09/2003US20030190306 HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constituent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
10/09/2003US20030190291 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
10/09/2003US20030190290 And dispensing devices for improved administration of opiod analgesics such as fentanyl, alfentanil, carfentanil, remifentanil, sufentanil, buprenorphine, morphine, diamorphine
10/09/2003US20030190289 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
10/09/2003US20030190288 Composition for osmotic decongestion and moisturization comprising water, ciliary stimulant, mucus thinning agent, osmotic agent, glycerin, preservative, wherein composition is alkaline and hypertonic with respect to cells of nasal mucosa
10/09/2003US20030190287 Comprising active material, propellant containing hydrofluoroalkane, cosolvent, low volatility component to increase mass median aerodynamic diameter of aerosol particles on actuation of inhaler
10/09/2003US20030190286 Propellant free buccal spray composition for transmucosal administration of pharmacologically active compound comprising 0.001-60 percent by weight immunosuppressants, mucolytics, glucocorticoids and 30-99 percent polar solvent
10/09/2003US20030190284 Agglomerated particles for aerosol drug delivery
10/09/2003US20030190283 Preparations for evaluating eliminative ability of stomach
10/09/2003US20030188740 Method for production of enhanced traceable immunizing drinking water and other liquid and gas products, devices for production and use thereof, and use of the enhanced products for immunizing living beings
10/09/2003US20030188679 Powdered mannitol and mannitol-containing compositions
10/09/2003US20030188676 Temperature activated systems
10/09/2003CA2481271A1 Clarithromycin formulations having improved bioavailability
10/09/2003CA2481269A1 Taste masked compositions of erythromycin a and derivatives thereof
10/09/2003CA2481236A1 Volume efficient controlled release dosage form
10/09/2003CA2480656A1 Bioadhesive directed somatic cell therapy
10/09/2003CA2480632A1 Drug delivery particle
10/09/2003CA2480631A1 Processes for manufacturing polymeric microspheres
10/09/2003CA2480630A1 Tissue treatment
10/09/2003CA2480377A1 Drug microparticles
10/09/2003CA2480270A1 Stabilized natural cannabinoid formulation
10/09/2003CA2480265A1 Cochleates made with purified soy phosphatidylserine
10/09/2003CA2480138A1 Transcellular drug delivery system
10/09/2003CA2480048A1 Chemiluminescent treatment of acne
10/09/2003CA2479995A1 Dispensing apparatus and cartridge
10/09/2003CA2479920A1 Microgel particles for the delivery of bioactive materials
10/09/2003CA2479915A1 Co-beadlet of dha and rosemary and methods of use
10/09/2003CA2479914A1 Meloxicam suppositories containing e.g. polyethylenglycol
10/09/2003CA2479148A1 A method for treating carrier particles and its use
10/09/2003CA2478470A1 Solubilization of weak bases
1 ... 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 ... 2991